CAJ | 학술논문

目的：观察131I治疗前后Graves病患者CXCL10和CCL22水平表达的变化，为Graves病的临床治疗提供新的思路。方法收集内分泌科2012年6月至2013年6月收治的Graves病患者46例(Graves病组)，另取同期我院体检中心检查的健康者40例作为对照(对照组)。CXCL10和CCL22表达的测定使用ELISA法， Th1和Th2细胞比例使用流式细胞仪检测。结果对照组CXCL10和CCL22的表达水平分别为(16.8±6.3) ng/L和(150.4±22.6) ng/L，显著低于Graves病组治疗前的(62.4±13.2) ng/L和(161.3±25.4) ng/L (P<0.05，P<0.01)，131I治疗后CXCL10和CCL22的表达水平均显著减低(P<0.05，P<0.01)，但CXCL10仍高于对照组(P<0.05)，而CCL22与对照组之间差异无统计学意义(P>0.05)。两组之间CXCL10/CCL22比值差异也有统计学意义(P<0.05)。正常对照组Th1和Th2细胞比例分别为(1.04±0.41)%和(2.28±0.67)%，显著低于Graves病组治疗前的(8.16±1.62)%和(2.82±0.73)%(P<0.05，P<0.01)，131I治疗后Th1和Th2细胞比例均出现了显著的减低(P<0.05，P<0.01)，但Th1细胞仍高于对照组(P<0.05)，而Th2细胞与对照组之间差异无统计学意义(P>0.05)。两组之间Th1/Th2比值差异也有统计学意义(P<0.05)。结论 Graves病患者中存在CXCL10和CCL22表达水平的升高，131I治疗后可降低CXCL10和CCL22表达水平，调节Th1/Th2细胞的失衡，CXCL10和CCL22因子的检测有可能作为131I治疗反应性的一个指标。
목적：관찰131I치료전후Graves병환자CXCL10화CCL22수평표체적변화，위Graves병적림상치료제공신적사로。방법수집내분비과2012년6월지2013년6월수치적Graves병환자46례(Graves병조)，령취동기아원체검중심검사적건강자40례작위대조(대조조)。CXCL10화CCL22표체적측정사용ELISA법， Th1화Th2세포비례사용류식세포의검측。결과대조조CXCL10화CCL22적표체수평분별위(16.8±6.3) ng/L화(150.4±22.6) ng/L，현저저우Graves병조치료전적(62.4±13.2) ng/L화(161.3±25.4) ng/L (P<0.05，P<0.01)，131I치료후CXCL10화CCL22적표체수평균현저감저(P<0.05，P<0.01)，단CXCL10잉고우대조조(P<0.05)，이CCL22여대조조지간차이무통계학의의(P>0.05)。량조지간CXCL10/CCL22비치차이야유통계학의의(P<0.05)。정상대조조Th1화Th2세포비례분별위(1.04±0.41)%화(2.28±0.67)%，현저저우Graves병조치료전적(8.16±1.62)%화(2.82±0.73)%(P<0.05，P<0.01)，131I치료후Th1화Th2세포비례균출현료현저적감저(P<0.05，P<0.01)，단Th1세포잉고우대조조(P<0.05)，이Th2세포여대조조지간차이무통계학의의(P>0.05)。량조지간Th1/Th2비치차이야유통계학의의(P<0.05)。결론 Graves병환자중존재CXCL10화CCL22표체수평적승고，131I치료후가강저CXCL10화CCL22표체수평，조절Th1/Th2세포적실형，CXCL10화CCL22인자적검측유가능작위131I치료반응성적일개지표。
Objective To detect the changes of CXCL10 and CCL22 in patients with Graves' disease (GD) after radioactive iodine therapy. Methods Forty-six patients with GD were enrolled into our study (GD group). An-other 40 healthy people were used as normal controls (control group). CXCL10 and CCL22 were detected by ELIAS. Th1 and Th2 cells was detected by flow cytometry. Results The expression levels of CXCL10 and CCL22 was (16.8±6.3) ng/L and (150.4±22.6) ng/L in control group, (62.4±13.2) ng/L and (161.3±25.4) ng/L in GD group (P<0.05, P<0.01). After 131I therapy, the expression levels of CXCL10 and CCL22 was significantly reduced (P<0.05, P<0.01), but CXCL10 was still higher than that in control group (P<0.05). There were also significant differences of CXCL10/CCL22 ratio between the two groups (P<0.05). The ratio of Th1 and Th2 cells were (1.04 ± 0.41)% and (2.28 ± 0.67)% in control group, which was significantly lower than (8.16 ± 1.62)% and (2.82 ± 0.73)% in GD group (P<0.05, P<0.01). After 131I therapy, the ratio of Th1 and Th2 cells were significantly reduced (P<0.05, P<0.01), but the ratio of Th1 cells were still higher than that in control group (P<0.05). There were also significant differences of Th1/Th2 ratio between the two groups (P<0.05). Conclusion Increased expression of CXCL10 and CCL22 is found in Graves' disease. 131I therapy can reduce the expression levels of CXCL10 and CCL22, which regulates the imbal-ance of Th1/Th2. Detection of CXCL10 and CCL22 may be used as the indicator of response to 131I treatment.